Full-Time
Develops medicines and vaccines for health issues
No salary listed
Senior, Expert
H1B Sponsorship Available
North Wales, PA, USA
Hybrid work model consisting of three total days on-site per week, Monday - Thursday, with Friday designated as a remote-working day.
Merck develops medicines and vaccines to address major health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients. Additionally, Merck supports healthcare professionals with resources like Merck Connect and Merck Manuals, setting it apart from competitors by emphasizing both patient care and professional education.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kenilworth, Illinois
Founded
1891
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Holidays
Paid Vacation
Paid Sick Leave
Hybrid Work Options
Flexible Work Hours
Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting. "Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said Sajith Wickramasekara, co-founder and CEO of Benchling. "By focusing on the modern demands of bioanalytical labs, we're delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle." "Sophisticated data management capabilities are integral to advancing vaccine research and development," said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. "We're thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling RD Cloud as their central source of truth for scientific data, analysis, and collaboration
Merck's Sean Finnerty was awarded a Community Appreciation Award for sharing how Merck is using AI to speed up and save software development costs.
Merck reveals launch of Susonity brand for cosmetics.
Rahway-based drugmaker Merck last month announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades by 2028.
Merck's mumps vaccine, part of the MMR shots, is confirmed to be far less effective than claimed, with courts acknowledging intentional fraud to maintain monopoly and avoid admitting failure.